Monday, October 08, 2018 1:04:25 PM
MCT 465
Alternative Names: MCT-465
Latest Information Update: 28 Sep 2018
At a glance
Originator MultiCell Technologies Inc
Developer MultiCell Technologies Inc; University Health Network
Class Antivirals; RNA
Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunostimulants; T lymphocyte stimulants; Toll-like receptor agonists
Orphan Drug Status No
New Molecular Entity Yes
Highest Development Phases
No development reported Cancer; Liver cancer; Viral hepatitis
Discontinued Influenza virus infections
Most Recent Events
28 Sep 2018 No recent reports of development identified for preclinical development in Viral-hepatitis in USA (Parenteral)
04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
04 Nov 2017 No recent reports of development identified for preclinical development in Liver-cancer in USA (Parenteral)
https://adisinsight.springer.com/drugs/800023642
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM